Evolus Jeuveau - Neurotoxins

Jeuveau, also known as PrabotulinumtoxinA-xvfs, is a neurotoxin type A product. It is similar to Botox (OnabotulinumtoxinA), Dysport (AbobotulinumtoxinA), and Xeomin (IncobotulinumtoxinA) and works by temporarily paralyzing muscles, which can reduce the appearance of facial wrinkles.

Jeuveau is specifically indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Glabellar lines are the lines between your eyebrows that could become prominent when you frown.

Jeuveau is produced by Evolus, and it’s the newest neurotoxin to be approved by the U.S. Food and Drug Administration (FDA) for aesthetic use, with its approval coming in February 2019.

Like other neurotoxin treatments, Jeuveau is administered via injections into specific muscles. The treatment is temporary, with the effects usually lasting between three to six months. It’s always important for treatments like this to be administered by a qualified healthcare professional to ensure the best results and safety.